Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken

Bronnen:

1. 1. Van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. EULAR 2018. Abstract LB0001.